Juvenile Idiopathic Arthritis

Rheumatic Disease Clinics of North America

Volumn 33, Issue 3, 2007, Pages 441-470

  Weiss, Jennifer E ^a   Ilowite, Norman T ^a,b  

^a SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AURANOFIN; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLD; GOLD DERIVATIVE; HYDROXYCHLOROQUINE; IBUPROFEN; IMMUNOGLOBULIN; INDOMETACIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE; STEROID; TOLMETIN; TRIAMCINOLONE HEXACETONIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG;

ADRENAL SUPPRESSION; BONE DENSITY; BONE MARROW SUPPRESSION; BONE NECROSIS; CALCIFICATION; CARDIOVASCULAR DISEASE; CATARACT; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC DISEASE; CLINICAL FEATURE; CUSHINGOID SYNDROME; CYTOKINE PRODUCTION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISABILITY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DYSLIPOPROTEINEMIA; ENTERITIS; GASTRITIS; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GLAUCOMA; GROWTH DISORDER; HEADACHE; HLA SYSTEM; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGLOBULIN DEFICIENCY; INFECTION; INFECTION COMPLICATION; INJECTION SITE ATROPHY; JUVENILE RHEUMATOID ARTHRITIS; LIVER TOXICITY; LUNG DISEASE; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MOUTH ULCER; NAUSEA; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PANCYTOPENIA; PATHOPHYSIOLOGY; PEPTIC ULCER; POLYARTHRITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RASH; REITER SYNDROME; REVIEW; RHEUMATIC FEVER; SARCOIDOSIS; SIDE EFFECT; SKIN DISEASE; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; UVEITIS; VOMITING;

EID: 34948832722     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2007.07.006     Document Type: Review

References (127)

1. Gare B.A. Juvenile arthritis-who gets it, where and when? A review of current data on incidence and prevalence. Clin Exp Rheumatol 17 (1999) 367-374
2. Prieur A.M., Le Gall E., Karman F., et al. Epidemiologic survey of juvenile chronic arthritis in France: comparison of data obtained from two different regions. Clin Exper Rheumatol 5 3 (1987) 217-223
3. Moe N., and Rygg M. Epidemiology of juvenile chronic arthritis in northern Norway: a ten-year retrospective study. Clin Exp Rheumatol 16 1 (1998) 99-101
4. Brewer Jr. E.J., Bass J., Baum J., et al. Current proposed revision of JRA criteria. Arthritis Rheum 20 (1977) 195-199
5. European League Against Rheumatism. EULAR Bulletin No. 4: nomenclature and classification of arthritis in children (1977), National Zeitung AG, Basel (Switzerland)
6. Petty R.E., Southwood T.R., Baum J., et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997. J Rheumatol 25 (1998) 1991-1994
7. Duffy CM, Colbert RA, Laxer RM, et al for the Executive Committee, Pediatric Section, American College of Rheumatology. Nomenclature and classification in chronic childhood arthritis: time for a change? Arthritis Rheum, in press.
8. Lang B.A., and Shore A. A review of current concepts on the pathogenesis of juvenile rheumatoid arthritis. J Rheumatol 17 Suppl 21 (1990) 1-15
9. Tucker L.B. Juvenile rheumatoid arthritis. Curr Opin Rheumatol 5 (1993) 619-628
10. Murray K.J., Grom A.A., Thompson S.D., et al. Contrasting cytokine profiles in the synovium of different forms of juvenile rheumatoid arthritis and juvenile spondyloarthropathy: prominence of interleukin 4 in restricted disease. J Rheumatol 25 (1998) 1388-1398
11. Thomson W., Barrett J.H., Donn R., et al. Juvenile idiopathic arthritis classified by the ILAR criteria: HLA associations in UK patients. Rheumatology 41 (2002) 1183-1189
12. Fishman D., Fauld G., Jeffrey R., et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels and an association with systemic onset juvenile chronic arthritis. J Clin Invest 102 (1998) 1369-1376
13. Woo P. Cytokines and juvenile idiopathic arthritis. Curr Rheumatol Rep 4 6 (2002) 452-457
14. Rosen P., Thompson S., and Glass D. Non-HLA gene polymorphisms in juvenile rheumatoid arthritis. Clin Exp Rheumatol 21 5 (2003) 650-656
15. Donn R., Alourfi Z., Zeggini E., et al., British Paediatric Rheumatology Study Group. A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. Arthritis Rheum 50 5 (2004) 1604-1610
16. Petty R.E., Cassidy J.T., and Sullivan D.B. Clinical correlates of antinuclear antibodies in juvenile rheumatoid arthritis. J Pediatr 83 3 (1973) 386-389
17. Mangee H., and Schauenstein K. Cytokines in juvenile rheumatoid arthritis (JRA). Cytokine 10 6 (1998) 471-480
18. Moore T.L. Immunopathogenesis of juvenile rheumatoid arthritis. Curr Opin Rheumatol 11 5 (1999) 377-387
19. Mangee H., Kenzian H., Gallistl S., et al. Serum cytokines in juvenile rheumatoid arthritis. Arthritis Rheum 2 (1995) 211-220
20. Cassidy J.T., Levinson J.E., Bass J.L., et al. A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum 29 2 (1986) 274-281
21. Calabro J.J. Juvenile rheumatoid arthritis. GP 40 1 (1969) 78-88
22. Al-Matar M.J., Petty R.E., Tucker L.B., et al. The early pattern of joint involvement predicts disease progression in children with oligoarticular (pauciarticular) juvenile rheumatoid arthritis. Arthritis Rheum 46 10 (2002) 2708-2715
23. Minden K., Niewerth M., Listing J., et al. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum 46 9 (2002) 2392-2401
24. Schaller J.G. Juvenile rheumatoid arthritis. Pediatr Rev 2 6 (1980) 163-174
25. Isdale I.C., and Bywaters E.G.L. The rash of rheumatoid arthritis and Still's disease. Q J Med 99 (1956) 377-387
26. Svantesson H., Akesson A., Eberhardt K., et al. Prognosis in juvenile rheumatoid arthritis with systemic onset. A follow-up study. Scand J Rheumatol 12 2 (1983) 139-144
27. Spiegel L.R., Schneider R., Lang B.A., et al. Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: a multicenter cohort study. Arthritis Rheum 43 11 (2000) 2402-2409
28. Calabro J.J., Holgerson W.B., Sonpal G.M., et al. Juvenile rheumatoid arthritis: a general review and report of 100 patients observed for 15 years. Semin Arthritis Rheum 5 (1976) 257-298
29. Cassidy J.T. Abnormality in the distribution of serum immunoglobulin concentration in juvenile rheumatoid arthritis. J Clin Invest 52 (1973) 1931-1936
30. Wallace C.A., and Levinson J.E. Juvenile rheumatoid arthritis: outcome and treatment for the 1990's. Rheum Dis Clin North Am 17 4 (1991) 891-904
31. Ramanan A.V., and Schneider R. Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol 30 (2003) 401-403
32. Silverman E.D., Miller III J.J., Bernstein B., et al. Consumption coagulopathy associated with systemic juvenile rheumatoid arthritis. J Pediatr 103 6 (1983) 872-876
33. Sawhney S., Woo P., and Murray K.J. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 85 5 (2001) 421-426
34. Grom A.A., and Passo M.D. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr 129 5 (1996) 630-632
35. Grom A.A. Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis?. Arthritis Rheum 50 3 (2004) 689-698
36. Henter J.I., Arico M., Egeler R.M., et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH Study Group of the Histiocyte Society. Med Pediatr Oncol 28 5 (1997) 342-347
37. Henter J.I., Samuelsson-Horne A., Aricò M., et al., for the Histiocyte Society. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 100 7 (2002) 2367-2373
38. Burgos-Vargas R., and Petty R.E. Juvenile ankylosing spondylitis. Rheum Dis Clin North Am 18 1 (1992) 123-142
39. Schaller J., Bitnum S., and Wedgwood R.J. Ankylosing spondylitis with childhood onset. J Pediatr 74 4 (1969) 505-516
40. Ansell B.M. Juvenile spondylitis and related disorders. In: Moll J.M.H. (Ed). Ankylosing spondylitis (1980), Churchill Livingstone, Edinburgh (UK) 120
41. Shore A., and Ansell B.M. Juvenile psoriatic arthritis-an analysis of 60 cases. J Pediatr 100 4 (1982) 529-535
42. Petty R.E., and Malleson P. Spondyloarthropathies of childhood. Pediatr Clin North Am 33 5 (1986) 1079-1096
43. Southwood T.R., Petty R.E., Malleson P.N., et al. Psoriatic arthritis in children. Arthritis Rheum 32 (1989) 1007-1013
44. Schneider R., and Passo M.H. Juvenile rheumatoid arthritis. Rheum Dis Clin North Am 28 3 (2002) 503-530
45. Anonymous. Guidelines for ophthalmologic examinations in children with juvenile rheumatoid arthritis. Section on rheumatology and section on ophthalmology. Pediatrics 92 2 (1993) 295-296
46. Bowyer S.L., Roettcher P.A., Higgins G.C., et al. Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis. J Rheumatol 30 (2003) 394-400
47. Schwartzman S., Flynn T., Barinstein L., et al. Infliximab therapy for resistant uveitis. Arthritis Rheum 46 9 (2002) S326
48. Reiff A., Syuji T., Sadeghi S., et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 44 6 (2001) 1411-1415
49. Barness L.A. Nutrition and nutritional disorders. In: Behrman R.E., and Kliegman R.M. (Eds). Nelson textbook of pediatrics (1992), W.B. Saunders, Philadelphia 105-147
50. Henderson C.J., and Lovell D.J. Nutritional aspects of juvenile rheumatoid arthritis. Rheum Dis Clin North Am 17 (1991) 403-413
51. Simon D., Lucidarme N., Prieur A.M., et al. Effects on growth and body composition of growth hormone treatment ion children with juvenile idiopathic arthritis requiring steroid therapy. J Rheumatol 30 (2003) 2492-2499
52. Pepmueller P.H., Cassidy J.T., Allen S.H., et al. Bone mineralization and bone metabolism in children with juvenile rheumatoid arthritis. Arthritis Rheum 39 5 (1996) 746-757
53. Knops N., Wulffraat N., Lodder S., et al. Resting energy expenditure and nutritional status in children with rheumatoid arthritis. J Rheumatol 26 (1999) 2039-2043
54. Ostrov B.E. Nutrition and pediatric rheumatic diseases. Hypothesis: cytokines modulate nutritional abnormalities in rheumatic diseases. J Rheumatol 19 Suppl 33 (1992) 49-53
55. Bechtold S., Ripperger P., Hafner R., et al. Growth hormone improves height in patients with juvenile idiopathic arthritis: 4-year data on a controlled study. J Pediatr 143 (2003) 512-519
56. Davies U.M., Jones J., Reeve J., et al. Juvenile rheumatoid arthritis: effects of disease activity and recombinant human growth hormone on insulin-like growth factor 1, insulin-like growth factor binding proteins 1 and 3. Arthritis Rheum 40 2 (1997) 332-340
57. De Benedetti F., Massa M., Robbioni P., et al. Correlation of IL-6 levels with joint involvement and thrombocytosis in systemic JCA. Arthritis Rheum 34 (1991) 1158-1163
58. Ansell B.M., and Bywaters E.G.L. Alternate-day corticosteroids therapy in juvenile chronic polyarthritis. J Rheumatol 1 (1974) 176-186
59. Saha M.T., Haapasaari J., Hannula S., et al. Growth hormone is effective in the treatment of severe growth retardation in children with juvenile chronic arthritis. Double blind placebo-controlled followup study. J Rheumatol 31 7 (2004) 1413-1417
60. Sherry D.D., Stein L.D., Reed A.M., et al. Prevention of leg length discrepancy in young children with pauciarticular juvenile rheumatoid arthritis by treatment with intraarticular steroids. Arthritis Rheum 42 11 (1999) 2330-2334
61. Lovell D.J., Henderson C.J., Cawkwell G., et al. Bone mineral content in juvenile rheumatoid arthritis and healthy controls. [abstract]. Arthritis Rheum 36 Suppl 9 (1993) S171
62. Henderson C.J., Specker B.L., Sierra R.I., et al. Total-body bone mineral content in non-corticosteroid-treated postpubertal females with juvenile rheumatoid arthritis. Frequency of osteopenia and contributing factors. Arthritis Rheum 43 3 (2000) 531-540
63. Lipnick R.N., Vieira N.E., Stuff J.E., et al. Calcium absorption and metabolism in children with juvenile rheumatoid arthritis assessed using stable isotopes. J Rheumatol 20 7 (1993) 1196-1200
64. Roth J., Palm C., Scheunemann E., et al. Musculoskeletal abnormalities of the forearm in patients with juvenile idiopathic arthritis relate mainly to bone geometry. Arthritis Rheum 50 4 (2004) 1277-1285
65. Hop R.J., Degan J.A., Galllagher J.C., et al. Estimation of bone mineral density in children with juvenile rheumatoid arthritis. J Rheumatol 18 (1991) 1235-1239
66. Rabinovich C.E. Bone metabolism in childhood rheumatic disease. Rheum Dis Clin North Am 28 3 (2002) 655-667
67. Cassidy J.T. Osteopenia and osteoporosis in children. Clin Exp Rheumatol 17 2 (1999) 245-250
68. Huygen A.C.J., Kuis W., and Sinnema G. Psychological, behavioral, and social adjustment in children and adolescents with juvenile chronic arthritis. Ann Rheum Dis 59 (2000) 276-282
69. Schanberg L.E., Anthony K.K., Gil K.M., et al. Daily pain and symptoms in children with polyarticular arthritis. Arthritis Rheum 48 5 (2003) 1390-1397
70. Sällfors C., Hallberg L.R.M., and Fasth A. Well-being in children with juvenile chronic arthritis. Clin Exp Rheumatol 2 (1993) 569-576
71. Henderson C.J., Lovell D.J., Specker B.L., et al. Physical activity in children with juvenile rheumatoid arthritis: quantification and evaluation. Arthritis Care Res 8 2 (1995) 114-119
72. Malleson P.N., Bennett S.M., MacKinnon M., et al. Physical fitness and its relationship to other indices of health status in children with chronic arthritis. J Rheumatol 23 (1996) 1059-1065
73. Hagglund K.J., Schopp L.M., Alberts K.R., et al. Predicting pain among children with juvenile rheumatoid arthritis. Arthritis Care Res 8 1 (1995) 36-42
74. Walco G.A., Varni J.W., and Ilowite N.T. Cognitive-behavioral pain management in children with juvenile rheumatoid arthritis. Pediatrics 89 (1992) 1075-1079
75. Ilowite N.T., Walco G.A., and Pochazchevsky R. Pain assessment in juvenile rheumatoid arthritis. The relationship between pain intensity and degree of joint inflammation. Ann Rheum Dis 51 (1992) 343-344
76. Singh G., Athreya B.H., Fries J.F., et al. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 37 (1994) 1761-1769
77. Dempster H., Porepa M., Young N., et al. The clinical meaning of functional outcome scores in children with juvenile arthritis. Arthritis Rheum 44 8 (2001) 1768-1774
78. Steinbrocker O., Traeger C.H., and Batterman R.C. Criteria for determination of progression of rheumatoid arthritis and functional capacity of patients with the disease. JAMA 140 (1949) 209
79. Andersson Gare B., and Fasth A. The natural history of juvenile chronic arthritis: a population based cohort study. II. Outcome. J Rheumatol 22 (1995) 308-319
80. Zak M., and Pederson F.K. Juvenile chronic arthritis into adulthood: a long-term follow-up study. Rheumatology 39 (2000) 198-204
81. David J., Cooper C., Hickey L., Lloyd J., et al. The functional and psychological outcomes of juvenile chronic arthritis in young adulthood. Br J Rheumatol 33 (1994) 876-881
82. Laaksonen A.L. A prognostic study of juvenile rheumatoid arthritis. Analysis of 544 cases. Acta Paediatr Scand Suppl 166 (1966) 1-163
83. Calabro J.J., Burnstein S.L., and Stanley H.L. Prognosis in JRA: a fifteen year follow-up of 100 patients. Arthritis Rheum 20 Suppl (1977) 285-290
84. Narayanan K., Rajendran C.P., Porkodi R., et al. A follow-up study of juvenile rheumatoid arthritis into adulthood. J Assoc Physicians India 50 (2002) 1039-1041
85. Foster H.E., Marshall N., Myers A., et al. Outcome in adults with juvenile rheumatoid arthritis. A quality of life study. Arthritis Rheum 48 3 (2003) 767-775
86. Cimaz R., and Ansell B.M. Sarcoidosis in the pediatric age. Clin Exp Rheum 20 (2002) 231-237
87. Klein-Gittelman M., Reiff A., and Silverman E.D. Systemic lupus erythematosus in childhood. Rheum Dis Clin North Am 28 3 (2002) 561-577
88. Panush R.S., Paraschiv D., and Dorff R.E. The tainted legacy of Hans Reiter. Semin Arthritis Rheum 32 4 (2003) 231-236
89. Szer I.S., Taylor E., and Steere A.C. The long-term course of Lyme arthritis in children. N Engl J Med 325 3 (1991) 159-163
90. Cabral D.A., and Tucker L.B. Malignancies in children who initially present with rheumatic complaints. J Pediatr 134 1 (1999) 53-57
91. Lang B.A., and Finlayson L.A. Naproxen-induced pseudoporphyria in patients with juvenile rheumatoid arthritis. J Pediatr 124 (1994) 639-642
92. Ilowite N.T. Current treatment of juvenile rheumatoid arthritis. Pediatrics 109 (2002) 109-115
93. Keenan G.F., Giannini E.H., and Athreya B.H. Clinically significant gastropathy associated with nonsteroidal antiinflammatory drug use in children with juvenile rheumatoid arthritis. J Rheumatol 22 6 (1995) 1149-1151
94. Len C., Hilario M.O., Kawakami E., et al. Gastroduodenal lesions in children with juvenile rheumatoid arthritis. Hepatogastroenterology 46 26 (1999) 991-996
95. Mulberg A.E., and Verhave M. Identification and treatment of nonsteroidal anti-inflammatory drug-induced gastroduodenal injury in children. Am J Dis Child 147 12 (1993) 1280-1281
96. Mamdani M., Juurlink D.N., Lee D.S., et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population based cohort study. Lancet 363 9423 (2004) 1751-1756
97. Krum H., Liew D., Aw J., et al. Cardiovascular effects of selective cyclooxygenase-2 inhibitors. Expert Rev Cardiovasc Ther 2 2 (2004) 265-270
98. Weir M.R., Sperling R.S., Reicin A., et al. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J 146 4 (2003) 591-604
99. Milojevic D.S., and Ilowite N.T. Treatment of rheumatic diseases in children: special considerations. Rheum Dis Clin North Am 28 (2002) 461-482
100. Eberhard B.A., Sison M.C., Gottlieb B.S., et al. A comparison of the intra-articular effectiveness of triamcinolone hexacetonide and triamcinolone acetonide in the treatment of children with juvenile rheumatoid arthritis. J Rheumatol 31 12 (2004) 2507-2512
101. Brostrom E., Hagelberg S., and Haglund-Akerlind Y. Effect of joint injections in children with JIA: evaluation by 3D-gait analysis. Acta Pediatr 93 7 (2004) 906-910
102. Zulian F., Martini G., Gobber D., et al. Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double blind trial. Rheumatology 43 (2004) 1288-1291
103. van Rossum M.A.J., Fiselier T.J.W., Franssen M.J.A.M., et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multi-center study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 41 (1998) 808-816
104. Burgos-Vargas R., Vazquez-Mellado J., Pacheco-Tena C., et al. A 26 week randomised, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis 61 10 (2002) 941-942
105. Cron R.Q., Sharma S., and Sherry D.D. Current treatment by United States and Canadian pediatric rheumatologists. J Rheumatol 26 (1999) 2036-2038
106. Ruperto N., Murray K.J., Gerlon V., et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 50 (2004) 2191-2201
107. Alsufyani K., Ortiz-Alvarez O., Cabral D.A., et al. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol 31 1 (2004) 179-182
108. Gianinni E.H., and Cassidy J.T. Methotrexate in juvenile rheumatoid arthritis. Do the benefits outweigh the risks?. Drug Saf 9 5 (1993) 325-339
109. Hunt P.G., Rose C.D., McIlvain-Simpson G., et al. The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis. A controlled study. J Rheumatol 24 (1997) 2230-2232
110. Passo M.H., and Hashkes P.J. Use of methotrexate in children. Bull Rheum Dis 47 5 (1998) 1-5
111. Silverman E., Mouy R., Spiegel L., et al. Durability of efficacy, safety and tolerability of leflunomide or methotrexate over 48 weeks of treatment in pediatric patients with juvenile rheumatoid arthritis. Arthritis Rheum 50 (2004) S90
112. Eberhard B.A., Laxer R.M., Andersson U., et al. Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis. Clin Exp Immunol 96 (1994) 260-266
113. Lovell D.J., Giannini E.H., Reiff A., et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 342 (2000) 763-769
114. Lovell D., Giannini E.H., Reiff A., et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Interim results from an ongoing multicenter, open label, extended-treatment trial. Arthritis Rheum 489 1 (2003) 218-226
115. Haapasaari J., Kautiainen H., Hannula S., et al. Good results from combining etanercept to prevailing DMARD therapy in refractory juvenile idiopathic arthritis. Clin Exp Rheumatol 20 6 (2002) 867-870
116. Mease P. Psoriatic arthritis: the role of THF inhibition and the effect of its inhibition with etanercept. Clin Exper Rheum 20 6 Suppl 28 (2002) S116-S121
117. Lahdenne P., Vähäsalo P., and Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 62 3 (2003) 245-247
118. Lovell DJ, Ruperto N, Cuttica R, et al. Randomized trial of infliximab plus methotrexate for the treatment of polyarticular juvenile rheumatoid arthritis. Presented at the American College of Rheumatology Annual Meeting, San Antonio, TX. October 16-21, 2004.
119. Lovell D.J., Ruperto N., Goodman S., et al. Preliminary data from the study of adalimumab in children with juvenile idiopathic arthritis. Arthritis Rheum 50 Suppl (2004) S436
120. Verbsky J.W., and White A.J. Effective use of the recombinant interleukin-1 receptor agonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 31 (2004) 2071-2075
121. Hendrickson M. Efficacy of anakinra in refractory systemic arthritis. Arthritis Rheum 50 9 (2004) S438
122. Irigoyen P.I., Olson J., Hom C., et al. Treatment of systemic onset juvenile rheumatoid arthritis with anakinra. Arthritis Rheum 50 9 (2004) S437
123. Pasquale V, Allantaz F, Arce E, et al. Dramatic clinical response to IL-1 blockade in systemic onset juvenile idiopathic arthritis. Presented at the American College of Rheumatology Annual Meeting, San Antonio, TX. 2004.
124. Yokota S., Miyama T., Imagawa T., et al. Phase II trial of anti-IL-6 antibody (MRA) for children with systemic onset juvenile idiopathic arthritis. Arthritis Rheum 48 9 Suppl (2003) S429
125. Yokota S. Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis. Curr Opin Rheumatol 15 5 (2003) 581-586
126. Choy E. Clinical experience with inhibition of interleukin-6. Rheum Dis Clin North Am 30 (2004) 405-415
127. De Kleer I.M., Brinkman D.M., Ferster A., et al. Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality and transplant related morbidity. Ann Rheum Dis 63 (2004) 1318-1326